title: Characterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving rats.
abstract: OBJECTIVE
  Drug administration modifies the balance of neurotransmitter-controlled ion channel activity and consequently the firing pattern of local neuronal populations and intracerebral field potentials. Fast Fourier Transformation of these field potentials provides an electropharmacogram depicting drug-induced changes within defined frequency ranges. The present investigation was undertaken to investigate the difference between atypical and typical antipsychotic drugs.
  
  
  METHODS
  Adult Fisher rats were implanted with 4 bipolar concentric steel electrodes using a stereotactic surgical procedure. Field potentials from four selected brain areas in freely moving rats were used to analyse the frequency content of the electropharmacogram after administration of 4 clinically used atypical antipsychotic drugs.
  
  
  RESULTS
  Atypical antipsychotics exerted effects similar to those reported for typical antipsychotics, on the electropharmacogram during the first hour after administration, whereas clear differences emerged during the second and third hour after dosing. During the latter period, only atypical antipsychotic drugs produced a statistically significant decrease in alpha1 and beta1 spectral power, especially within the striatum, somewhat less in the cortex.
  
  
  CONCLUSIONS
  Previous studies have attributed alpha1 frequency changes to the influence of 5-hydroxytryptamine (5-HT) and the present data are consistent with additional binding of atypical drugs to 5-HT receptors. This implies that a change in the balance between dopaminergic and 5-hydroxytryptaminergic neurotransmission (activation of both) is likely to underlie the relative lack of extrapyramidal side effects characteristic of atypical antipsychotics and also for their higher efficacy in the treatment of mood and cognition deficits in schizophrenics.
authors: Justus-Liebig-University Giessen, Hessen, Germany. w.dimpfel@neurocode-ag.com
authors: W
authors: W
authors: Dimpfel
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000494:pharmacology; D003024:Clozapine / Q000008:administration & dosage / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects* / Q000502:physiology; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography / Q000187:drug effects* / Q000379:methods; D005260:Female; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology; D007274:Injections, Intraperitoneal; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009068:Movement; D000077152:Olanzapine; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000187:drug effects / Q000502:physiology; D000069348:Quetiapine Fumarate; D051381:Rats; D011916:Rats, Inbred F344; D012154:Reticular Formation / Q000187:drug effects / Q000502:physiology; D018967:Risperidone / Q000008:administration & dosage / Q000494:pharmacology; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine
references: Eur Neuropsychopharmacol. 1994 Dec;4(4):491-501
references: 7894260
references: Int Clin Psychopharmacol. 1994 Spring;9(1):17-24
references: 7910833
references: Br J Clin Pharmacol. 1999 Sep;48(3):323-30
references: 10510142
references: Eur Neuropsychopharmacol. 2005 Dec;15(6):673-82
references: 16009538
references: J Coll Physicians Surg Pak. 2006 Aug;16(8):556-62
references: 16899192
references: Schizophr Res. 2006 Dec;88(1-3):265-74
references: 16916599
references: Psychopharmacology (Berl). 2007 May;191(4):995-1004
references: 17333135
references: Neuropsychopharmacology. 2007 Aug;32(8):1715-26
references: 17251913
references: J Pharmacol Exp Ther. 1989 Oct;251(1):238-46
references: 2571717
references: J Psychiatry Neurosci. 2000 Mar;25(2):161-6
references: 10740989
references: Neuropsychopharmacology. 2000 Jun;22(6):642-9
references: 10788763
references: Psychopharmacology (Berl). 2001 Nov;158(3):281-8
references: 11713618
references: CNS Drugs. 2002;16(1):23-45
references: 11772117
references: Drugs. 2002;62(8):1217-51
references: 12010089
references: Br J Psychiatry. 2002 Oct;181:271-5
references: 12356650
references: Methods Find Exp Clin Pharmacol. 2002;24 Suppl C:85-9
references: 12575491
references: Eur J Med Res. 2003 May 30;8(5):199-207
references: 12844474
references: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1145-58
references: 14642973
references: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72
references: 14642974
references: Nature. 1976 Jun 24;261(5562):717-9
references: 945467
references: Neuropsychobiology. 1986;16(2-3):163-8
references: 3587575
references: Neuropsychobiology. 1987;18(4):212-8
references: 2841622
references: Psychopharmacology (Berl). 1989;98(3):297-303
references: 2568652
references: Psychopharmacology (Berl). 1992;107(2-3):195-202
references: 1352051
references: Psychopharmacology (Berl). 1999 Jun;144(3):272-8
references: 10435394